E-resources
Peer reviewed
-
Morrison, Chris
Nature biotechnology, 04/2015, Volume: 33, Issue: 4Journal Article
The first cyclin-dependent kinase 4/6 (CDK4/6) inhibitor was okayed by the US Food and Drug Administration (FDA) February 3, as New York-based Pfizer received accelerated approval for Ibrance (palbociclib) based on phase 2 data. The drugs go-ahead is for use as a frontline treatment in combination with letrozole (Femara), a standard anti-estrogen therapy, in postmenopausal women with estrogen receptor (ESR)-positive human epidermal growth factor receptor-2 (HER2)-negative (ESR+/HER2) advanced breast cancer.
Author
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.